628 related articles for article (PubMed ID: 19348592)
1. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.
Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH;
Clin Infect Dis; 2009 May; 48(10):1459-66. PubMed ID: 19348592
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
3. Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.
Engsig FN; Hansen AB; Omland LH; Kronborg G; Gerstoft J; Laursen AL; Pedersen C; Mogensen CB; Nielsen L; Obel N
J Infect Dis; 2009 Jan; 199(1):77-83. PubMed ID: 19007313
[TBL] [Abstract][Full Text] [Related]
4. Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L; Palacios R; Valencia E; Saballs P; Sirera G; Santos I; Baldobí F; Alegre M; Goyenechea A; Pedreira J; González del Castillo J; Martínez-Lacasa J; Ocampo A; Alsina M; Santos J; Podzamczer D; González-Lahoz J;
Clin Infect Dis; 2008 Aug; 47(3):410-7. PubMed ID: 18582203
[TBL] [Abstract][Full Text] [Related]
5. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.
Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M;
Clin Infect Dis; 2005 Aug; 41(3):361-72. PubMed ID: 16007534
[TBL] [Abstract][Full Text] [Related]
6. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
7. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
8. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization for pneumonia among individuals with and without HIV infection, 1995-2007: a Danish population-based, nationwide cohort study.
Sogaard OS; Lohse N; Gerstoft J; Kronborg G; Ostergaard L; Pedersen C; Pedersen G; Sørensen HT; Obel N
Clin Infect Dis; 2008 Nov; 47(10):1345-53. PubMed ID: 18834317
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.
Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC;
Antivir Ther; 2007; 12(6):889-97. PubMed ID: 17926643
[TBL] [Abstract][Full Text] [Related]
12. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
[TBL] [Abstract][Full Text] [Related]
14. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy.
Bossolasco S; Calori G; Moretti F; Boschini A; Bertelli D; Mena M; Gerevini S; Bestetti A; Pedale R; Sala S; Sala S; Lazzarin A; Cinque P
Clin Infect Dis; 2005 Mar; 40(5):738-44. PubMed ID: 15714422
[TBL] [Abstract][Full Text] [Related]
16. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
17. [Survival and immune response of rural HIV/AIDS patients after free antiretroviral therapy].
Ding YY; Jia WQ; Wang JS; Dong SL; Yang QH; Zhou RY; Qu SX; Lu LX; Wei J; Qiao XC; Gao MY; Guo XL; Zhang TJ; Wu ZY; He N
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Dec; 29(12):1176-80. PubMed ID: 19173958
[TBL] [Abstract][Full Text] [Related]
18. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy.
Berenguer J; Miralles P; Arrizabalaga J; Ribera E; Dronda F; Baraia-Etxaburu J; Domingo P; Márquez M; Rodriguez-Arrondo FJ; Laguna F; Rubio R; Lacruz Rodrigo J; Mallolas J; de Miguel V;
Clin Infect Dis; 2003 Apr; 36(8):1047-52. PubMed ID: 12684918
[TBL] [Abstract][Full Text] [Related]
19. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era.
El Amari EB; Toutous-Trellu L; Gayet-Ageron A; Baumann M; Cathomas G; Steffen I; Erb P; Mueller NJ; Furrer H; Cavassini M; Vernazza P; Hirsch HH; Bernasconi E; Hirschel B;
AIDS; 2008 May; 22(9):1019-28. PubMed ID: 18520345
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy.
Lortholary O; Poizat G; Zeller V; Neuville S; Boibieux A; Alvarez M; Dellamonica P; Botterel F; Dromer F; Chêne G
AIDS; 2006 Nov; 20(17):2183-91. PubMed ID: 17086058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
